社区获得性肺炎:综述
该综述指出,美国CAP每年约导致140万次急诊就诊、74万例住院和4.1万例死亡。诊断需2项以上肺炎体征(如体温>38℃或≤36℃;白细胞<4000/μL或>10000/μL)或症状(如新发或加重的咳嗽或呼吸困难)并伴一致的影像学表现(如气腔密度增高),且无其他解释。住院CAP患者中仅38%明确病原体,其中高达40%为病毒,约15%为肺炎链球菌。所有CAP患者在社区病毒流行时应检测COVID-19和流感。住院无耐药菌风险者可予β-内酰胺/大环内酯类联合治疗(如头孢曲松联合阿奇霉素)至少3天;重症CAP发生后24小时内使用全身糖皮质激素可能降低28天死亡率。
要点
- 住院CAP无耐药菌风险者可予β-内酰胺/大环内酯类联合治疗,如头孢曲松联合阿奇霉素,至少3天。
- CAP诊断需2项以上体征(体温>38℃或≤36℃;白细胞<4000/μL或>10000/μL)或症状(新发或加重咳嗽或呼吸困难)伴一致影像学表现且无其他解释。
- 所有CAP患者在社区COVID-19和流感流行时应检测这两种病毒,因诊断可能影响治疗(如抗病毒治疗)和感染预防策略。
- 重症CAP发生后24小时内使用全身糖皮质激素可能降低28天死亡率。
- 住院CAP患者中仅38%明确病原体,其中高达40%为病毒,约15%为肺炎链球菌。
适用人群与场景
- CAP患者,尤其是≥65岁老年人及有基础肺病、吸烟或免疫抑制者,为CAP及其并发症(脓毒症、急性呼吸窘迫综合征、死亡)最高危人群。
- 高达10%的CAP患者住院,其中高达1/5需重症监护。
诊断标准与关键阈值
- CAP诊断:患者有2项以上肺炎体征(如体温>38℃或≤36℃;白细胞计数<4000/μL或>10000/μL)或症状(如新发或加重的咳嗽或呼吸困难),并伴一致的影像学表现(如气腔密度增高),且无其他解释。
处置流程与药物剂量
- 所有CAP患者在社区COVID-19和流感流行时应检测COVID-19和流感,因诊断可能影响治疗(如抗病毒治疗)和感染预防策略。
- 若流感或COVID-19检测阴性或病原体不太可能时,可经验性覆盖最可能的细菌病原体。
- 选择经验性抗菌治疗时,临床医生应考虑疾病严重程度,评估细菌感染或耐药感染的可能性以及抗菌药物过度使用的危害风险。
- 住院无耐药菌风险因素的患者可予β-内酰胺/大环内酯类联合治疗,如头孢曲松联合阿奇霉素,至少3天。
- 重症CAP发生后24小时内使用全身糖皮质激素可能降低28天死亡率。
红旗征与不能漏的情况
- CAP可导致脓毒症、急性呼吸窘迫综合征或死亡。
研究设计与关键结果
- 美国CAP每年约导致140万次急诊就诊、74万例住院和4.1万例死亡。
- 住院CAP患者中仅38%明确病原体;其中高达40%为病毒,约15%为肺炎链球菌。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 住院CAP无耐药菌风险者可按β-内酰胺/大环内酯类联合治疗(如头孢曲松联合阿奇霉素)至少3天。
- CAP患者在社区COVID-19和流感流行时应检测这两种病毒。
- 重症CAP发生后24小时内可考虑使用全身糖皮质激素以可能降低28天死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Community-acquired pneumonia (CAP) results in approximately 1.4 million emergency department visits, 740 000 hospitalizations, and 41 000 deaths in the US annually.
OBSERVATIONS: Community-acquired pneumonia can be diagnosed in a patient with 2 or more signs (eg, temperature >38 °C or ≤36 °C; leukocyte count <4000/μL or >10 000/μL) or symptoms (eg, new or increased cough or dyspnea) of pneumonia in conjunction with consistent radiographic findings (eg, air space density) without an alternative explanation. Up to 10% of patients with CAP are hospitalized; of those, up to 1 in 5 require intensive care. Older adults (≥65 years) and those with underlying lung disease, smoking, or immune suppression are at highest risk for CAP and complications of CAP, including sepsis, acute respiratory distress syndrome, and death. Only 38% of patients hospitalized with CAP have a pathogen identified. Of those patients, up to 40% have viruses identified as the likely cause of CAP, with Streptococcus pneumoniae identified in approximately 15% of patients with an identified etiology of the pneumonia. All patients with CAP should be tested for COVID-19 and influenza when these viruses are common in the community because their diagnosis may affect treatment (eg, antiviral therapy) and infection prevention strategies. If test results for influenza and COVID-19 are negative or when the pathogens are not likely etiologies, patients can be treated empirically to cover the most likely bacterial pathogens. When selecting empirical antibacterial therapy, clinicians should consider disease severity and evaluate the likelihood of a bacterial infection-or resistant infection-and risk of harm from overuse of antibacterial drugs. Hospitalized patients without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days. Systemic corticosteroid administration within 24 hours of development of severe CAP may reduce 28-day mortality.
CONCLUSIONS: Community-acquired pneumonia is common and may result in sepsis, acute respiratory distress syndrome, or death. First-line therapy varies by disease severity and etiology. Hospitalized patients with suspected bacterial CAP and without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days.
参考来源
- Vaughn VM, Dickson RP, Horowitz JK, et al. Community-Acquired Pneumonia: A Review. JAMA. 2024. PMID: 39283629. doi:10.1001/jama.2024.14796
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。